Lumos Diagnostics secures national contract for FebriDx®

Lumos Diagnostics (ASX:LDX) has secured a national contract with MediGroup for the placement of their rapid point-of-care test, FebriDx®. This contract will make FebriDx® available to all MediGroup members in the United States, following its clearance by the US Food and Drug Administration in July 2023.

Lumos CEO and Managing Director, Doug Ward, on the national contract with MediGroup

We are very pleased to see FebriDx® added to MediGroup's national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx.

Lumos Diagnostics expands market reach with MediGroup contract

Lumos Diagnostics (ASX:LDX) has expanded its market reach by securing a national contract with MediGroup for the placement of FebriDx®. This strategic move will make FebriDx® available to all MediGroup members in the United States, providing an opportunity for increased adoption of Lumos' rapid point-of-care respiratory test. The company's CEO, Doug Ward, emphasized the significance of this partnership, highlighting MediGroup's extensive membership base and its potential to enhance distribution coverage for FebriDx®. This development aligns with Lumos' commitment to advancing point-of-care diagnostic technologies and expanding access to its innovative solutions.